High-grade surface Osteosarcoma – Data from the Cooperative Osteosarcoma Study Group (COSS)

Pediatric Hematology Oncology Journal Pub Date : 2026-03-01 Epub Date: 2026-03-06 DOI:10.1016/j.phoj.2026.100809
Patricia J. Schäfenacker , Stefanie Hecker-Nolting , Stefan Bielack , Matthias Kevric , Benjamin Sorg , Arndt Borkhardt , Bernd Hertenstein , Peter Reichardt , Daniel A. Müller , Leo Kager , Mathias Werner , Claudia Blattmann
{"title":"High-grade surface Osteosarcoma – Data from the Cooperative Osteosarcoma Study Group (COSS)","authors":"Patricia J. Schäfenacker ,&nbsp;Stefanie Hecker-Nolting ,&nbsp;Stefan Bielack ,&nbsp;Matthias Kevric ,&nbsp;Benjamin Sorg ,&nbsp;Arndt Borkhardt ,&nbsp;Bernd Hertenstein ,&nbsp;Peter Reichardt ,&nbsp;Daniel A. Müller ,&nbsp;Leo Kager ,&nbsp;Mathias Werner ,&nbsp;Claudia Blattmann","doi":"10.1016/j.phoj.2026.100809","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>High-grade surface osteosarcoma (HGSOS) is a rare subtype of osteosarcoma, accounting for approximately 1% of all cases. Due to its rarity, data on clinical characteristics, treatment, and outcomes remain limited.</div></div><div><h3>Methods</h3><div>Patients with a histologically confirmed diagnosis of HGSOS registered in the Cooperative Osteosarcoma Study Group (COSS) between 1978 and 2021 were retrospectively analyzed. Event-free survival (EFS) and overall survival rate (OAS) were estimated using Kaplan–Meier analysis, and potential prognostic factors were explored.</div></div><div><h3>Results</h3><div>Thirty-one patients met the inclusion criteria. Median age at diagnosis was 16.8 years, and tumors were predominantly located in the extremities (83.9%). Primary metastatic disease at diagnosis was rare (n = 1). At a median follow-up of 5.33 years, 3- and 5-year EFS were 79.5% and 75.3%, while 3- and 5-year OAS were 82.7% and 78.1%, respectively. Larger tumor volume, poor histological response to neoadjuvant chemotherapy, and early recurrence were associated with inferior outcomes in univariate analyses. In multivariate analysis, tumor localization in an extremity was identified as the only independent predictor of overall survival.</div></div><div><h3>Conclusions</h3><div>Patients with HGSOS treated within multimodal osteosarcoma protocols demonstrated favorable survival outcomes. Prognostic interpretation is limited by the small cohort size; however, tumor localization, tumor volume, histological response, and timing of recurrence appear to influence outcome. Larger collaborative studies are needed to further define prognostic factors in this rare tumor entity.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 1","pages":"Article 100809"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124526000070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

High-grade surface osteosarcoma (HGSOS) is a rare subtype of osteosarcoma, accounting for approximately 1% of all cases. Due to its rarity, data on clinical characteristics, treatment, and outcomes remain limited.

Methods

Patients with a histologically confirmed diagnosis of HGSOS registered in the Cooperative Osteosarcoma Study Group (COSS) between 1978 and 2021 were retrospectively analyzed. Event-free survival (EFS) and overall survival rate (OAS) were estimated using Kaplan–Meier analysis, and potential prognostic factors were explored.

Results

Thirty-one patients met the inclusion criteria. Median age at diagnosis was 16.8 years, and tumors were predominantly located in the extremities (83.9%). Primary metastatic disease at diagnosis was rare (n = 1). At a median follow-up of 5.33 years, 3- and 5-year EFS were 79.5% and 75.3%, while 3- and 5-year OAS were 82.7% and 78.1%, respectively. Larger tumor volume, poor histological response to neoadjuvant chemotherapy, and early recurrence were associated with inferior outcomes in univariate analyses. In multivariate analysis, tumor localization in an extremity was identified as the only independent predictor of overall survival.

Conclusions

Patients with HGSOS treated within multimodal osteosarcoma protocols demonstrated favorable survival outcomes. Prognostic interpretation is limited by the small cohort size; however, tumor localization, tumor volume, histological response, and timing of recurrence appear to influence outcome. Larger collaborative studies are needed to further define prognostic factors in this rare tumor entity.
高级别表面骨肉瘤-来自合作骨肉瘤研究组(COSS)的数据
高级别表面骨肉瘤(high -grade surface osteosarcoma, HGSOS)是一种罕见的骨肉瘤亚型,约占所有病例的1%。由于其罕见性,临床特征、治疗和结果的数据仍然有限。方法回顾性分析1978年至2021年间在合作骨肉瘤研究组(COSS)登记的组织学确诊为HGSOS的患者。使用Kaplan-Meier分析估计无事件生存期(EFS)和总生存率(OAS),并探讨潜在的预后因素。结果31例患者符合纳入标准。诊断时的中位年龄为16.8岁,肿瘤主要位于四肢(83.9%)。诊断时的原发性转移性疾病很少见(n = 1)。中位随访5.33年,3年和5年EFS分别为79.5%和75.3%,而3年和5年OAS分别为82.7%和78.1%。在单因素分析中,较大的肿瘤体积、对新辅助化疗的不良组织学反应和早期复发与较差的预后相关。在多变量分析中,肿瘤定位于肢体被确定为总生存的唯一独立预测因子。结论:采用多模式骨肉瘤方案治疗HGSOS患者具有良好的生存预后。由于队列规模小,预后解释受到限制;然而,肿瘤定位、肿瘤体积、组织学反应和复发时间似乎会影响结果。需要更大规模的合作研究来进一步确定这种罕见肿瘤实体的预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书